DrugDashboards

NP Thyroid 60

Levothyroxine, Liothyronine · LEVOTHYROXINE 38 ug/1; LIOTHYRONINE 9 ug/1 · Tablet · Oral · Acella Pharmaceuticals, LLC

NDC 42192-0330-01 · 100 TABLET in 1 BOTTLE · UNAPPROVED DRUG OTHER · View full market →

The short version

8 companies supply this market — a reasonable cushion if one runs into trouble. The price has held steady around $0.6655 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.25$0.5$0.75Apr 2017Sep 2026$0.6655
109 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$19.96
#90 count
$59.89

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$840,777
22,594 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

0● Low risk

Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for levothyroxine, liothyronine (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
—
TE code
—
Approval date
—
Patents / exclusivity
—

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class I · TerminatedApr 29, 2021
    Acella Pharmaceuticals, LLC — Subpotent Drug
  • Class I · TerminatedApr 29, 2021
    Acella Pharmaceuticals, LLC — Subpotent Drug
  • Class I · TerminatedApr 29, 2021
    Acella Pharmaceuticals, LLC — Subpotent Drug
  • Class I · TerminatedApr 29, 2021
    Acella Pharmaceuticals, LLC — Subpotent Drug
  • Class I · TerminatedApr 29, 2021
    Acella Pharmaceuticals, LLC — Subpotent Drug
  • Class I · TerminatedSep 17, 2020
    Acella Pharmaceuticals, LLC — Subpotent Drug: FDA analysis found these products to be less than the labeled claim for the levothyroxine (T4) portion of the product.
  • Class I · TerminatedSep 17, 2020
    Acella Pharmaceuticals, LLC — Subpotent Drug: FDA analysis found these products to be less than the labeled claim for the levothyroxine (T4) portion of the product.
  • Class I · TerminatedMay 22, 2020
    Acella Pharmaceuticals, LLC — Superpotent Drug.
  • Class I · TerminatedMay 22, 2020
    Acella Pharmaceuticals, LLC — Superpotent Drug.
  • Class I · TerminatedMay 22, 2020
    Acella Pharmaceuticals, LLC — Superpotent Drug.

Manufacturers of Levothyroxine, Liothyronine (Tablet)

LabelerStrengthFirst seenLast seen
A-S Medication SolutionsLEVOTHYROXINE 57 ug/1; LIOTHYRONINE 13.5 ug/1Jul 15, 2026Sep 2, 2026
A-S Medication SolutionsLEVOTHYROXINE 19 ug/1; LIOTHYRONINE 4.5 ug/1Jul 15, 2026Sep 2, 2026
A-S Medication SolutionsLEVOTHYROXINE 38 ug/1; LIOTHYRONINE 9 ug/1Jul 15, 2026Sep 2, 2026
Acella Pharmaceuticals, LLCLIOTHYRONINE 2.25 ug/1; LEVOTHYROXINE 9.5 ug/1Aug 26, 2026Sep 2, 2026
Acella Pharmaceuticals, LLCLEVOTHYROXINE 19 ug/1; LIOTHYRONINE 4.5 ug/1Jul 15, 2026Sep 2, 2026
Acella Pharmaceuticals, LLCLEVOTHYROXINE 57 ug/1; LIOTHYRONINE 13.5 ug/1Jul 15, 2026Sep 2, 2026
Acella Pharmaceuticals, LLCLEVOTHYROXINE 38 ug/1; LIOTHYRONINE 9 ug/1Jul 15, 2026Sep 2, 2026
Acella Pharmaceuticals, LLCLEVOTHYROXINE 76 ug/1; LIOTHYRONINE 18 ug/1Jul 15, 2026Sep 2, 2026
Asclemed USA, Inc.LEVOTHYROXINE 38 ug/1; LIOTHYRONINE 9 ug/1Jul 15, 2026Sep 2, 2026
Asclemed USA, Inc.LEVOTHYROXINE 76 ug/1; LIOTHYRONINE 18 ug/1Jul 15, 2026Sep 2, 2026
Asclemed USA, Inc.LEVOTHYROXINE 19 ug/1; LIOTHYRONINE 4.5 ug/1Jul 15, 2026Sep 2, 2026
Asclemed USA, Inc.LEVOTHYROXINE 9.5 ug/1; LIOTHYRONINE 2.25 ug/1Jul 15, 2026Sep 2, 2026
Asclemed USA, Inc.LEVOTHYROXINE 57 ug/1; LIOTHYRONINE 13.5 ug/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackLEVOTHYROXINE 9.5 ug/1; LIOTHYRONINE 2.25 ug/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackLEVOTHYROXINE 19 ug/1; LIOTHYRONINE 4.5 ug/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackLEVOTHYROXINE 38 ug/1; LIOTHYRONINE 9 ug/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackLEVOTHYROXINE 76 ug/1; LIOTHYRONINE 18 ug/1Jul 15, 2026Sep 2, 2026
Direct RxLIOTHYRONINE 4.5 ug/1; LEVOTHYROXINE 19 ug/1Aug 26, 2026Sep 2, 2026
Northwind Health Company, LLCLEVOTHYROXINE 38 ug/1; LIOTHYRONINE 9 ug/1Jul 15, 2026Sep 2, 2026
NuCare Pharmaceuticals,Inc,LEVOTHYROXINE 38 ug/1; LIOTHYRONINE 9 ug/1Jul 15, 2026Sep 2, 2026
NuCare Pharmaceuticals,Inc.LEVOTHYROXINE 19 ug/1; LIOTHYRONINE 4.5 ug/1Jul 15, 2026Sep 2, 2026
Acella Pharmaceuticals, LLCLIOTHYRONINE 9.5 ug/1; LEVOTHYROXINE 2.25 ug/1Jul 22, 2026Aug 19, 2026
Direct RxLIOTHYRONINE 19 ug/1; LEVOTHYROXINE 4.5 ug/1Jul 22, 2026Aug 19, 2026
Acella Pharmaceuticals, LLCLEVOTHYROXINE 9.5 ug/1; LIOTHYRONINE 2.25 ug/1Jul 15, 2026Jul 15, 2026
Direct RxLEVOTHYROXINE 19 ug/1; LIOTHYRONINE 4.5 ug/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "NP Thyroid 60 — NDC 42192-0330-01," retrieved September 3, 2026, https://drugdashboards.com/drug/42192033001.

Free to cite with attribution — see how the data is put together.